William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – William Blair decreased their Q1 2025 earnings per share (EPS) estimates for Nkarta in a research note issued to investors on Thursday, March 27th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.44) for the quarter, down from their prior forecast of ($0.42). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06.

A number of other equities analysts have also commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Nkarta in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday. Finally, Stifel Nicolaus decreased their price target on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Nkarta has a consensus rating of “Buy” and an average price target of $14.86.

Nkarta Trading Up 1.5 %

NKTX opened at $2.00 on Monday. Nkarta has a 12 month low of $1.31 and a 12 month high of $11.84. The company has a market cap of $141.92 million, a PE ratio of -1.06 and a beta of 0.90. The company has a 50 day moving average of $1.99 and a 200 day moving average of $2.82.

Institutional Trading of Nkarta

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its stake in Nkarta by 138.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after acquiring an additional 1,474,560 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% during the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock valued at $6,277,000 after purchasing an additional 686,229 shares during the last quarter. Jefferies Financial Group Inc. increased its position in shares of Nkarta by 901.7% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock valued at $6,236,000 after purchasing an additional 2,254,219 shares during the last quarter. Tang Capital Management LLC raised its holdings in shares of Nkarta by 252.9% during the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock valued at $5,711,000 after buying an additional 1,643,719 shares in the last quarter. Finally, Alyeska Investment Group L.P. lifted its position in Nkarta by 23.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company’s stock worth $3,323,000 after buying an additional 250,000 shares during the last quarter. 80.54% of the stock is owned by institutional investors.

Insider Buying and Selling at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.70% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.